Oksiconazole (Oxiconazolum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Antifungal means

Included in the formulation
  • Mifungar®
    cream externally 
    Zentiva c.s.     Czech Republic
    • АТХ:

    D.01.A.C   Imidazole derivatives

    D.01.A.C.11   Oksiconazole

    Pharmacodynamics:

    The imidazole derivative.

    "Target" for the action of the drug - 14-α-demethylase, which is part of a group of enzymes known collectively as cytochrome P450. All enzymes of the cytochrome P450 group contain a hematinic iron-containing pigment. Oksiconazole binds to the iron atom of the hematinic group and inactivates 14-α-demethylase, which leads to a disruption in the synthesis of ergosterol and the accumulation of lanosterol and other sterols. Their incorporation into the membrane instead of ergosterol significantly disrupts the structure and function of the fungal cell membrane. Reduction of the synthesis of ergosterol, as well as the accumulation of 14α-methyl sterols, destroys the densely packed acyl chains of phospholipids in fungal membranes. Destabilization of the fungal membrane leads to dysfunction of membrane enzymes, including those involved in the electron transport chain, and ultimately - to cell death.

    Is active in: Epidermophyton, Microsporum, Trichophyton, Candida albicans, Malassezia furfur (Pityrosporum orbiculare).

    Pharmacokinetics:

    Poorly absorbed from the surface of the body, metabolized in the liver, excreted by the kidneys for 5 days.

    Indications:

    Vaginal infections, fungal diseases of the skin (including the skin of the hairy parts of the body), which are caused by sensitive fungi.

    ICD-10

    I.B35-B49.B35.0   Mycosis of the beard and head

    I.B35-B49.B35.2   Mycosis brushes

    I.B35-B49.B35.3   Mycosis of the feet

    I.B35-B49.B35.4   Mycosis of the trunk

    I.B35-B49.B35.6   Epidermophytosis inguinal

    I.B35-B49.B36.0   Multicolored lichen

    I.B35-B49.B37.2   Candidiasis of skin and nails

    I.B35-B49.B37.3   Candidiasis of the vulva and vagina (N77.1 *)

    I.B35-B49.B48   Other mycoses, not elsewhere classified

    Contraindications:

    Hypersensitivity, age to 6 years.

    Carefully:

    Pregnancy, breast-feeding, liver disease.

    Pregnancy and lactation:Recommendations for FDA - category B. Not recommended for pregnancy and lactation.
    Dosing and Administration:

    Dosing regimen is individual.

    Outwardly. The drug is applied a thin layer on the affected areas 1 time per day (at night). Duration of treatment with mycosis skin 2 weeks, with mycosis stop 1 month.

    To prevent recurrence, treatment is continued for 1-2 weeks after complete recovery.

    Side effects:

    Hypersensitivity (cross-over with all azoles), other anaphylactic, anaphylactoid and allergic reactions (including Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria).

    Dizziness, headache, drowsiness.

    Nausea, vomiting, constipation, diarrhea, loss of appetite, abdominal pain, hepatotoxicity (hepatocellular and cholestatic), increased aminotransferase activity, hepatitis, liver failure, cardiac failure.

    Hyperglycemia, hypertriglyceridemia, neutropenia, peripheral neuropathy, itching, pulmonary edema, lengthening the interval Q-T, convulsions, pirouette tachycardia.

    Local: itching, burning sensation in the vagina, rashes in the external genital organs; allergic reactions. Erythema, tingling, burning, irritation.

    Overdose:

    Cardiopulmonary insufficiency.

    Symptoms: with accidental ingestion - nausea, vomiting.

    Treatment: gastric lavage, symptomatic therapy.

    Interaction:

    When administered concomitantly with lovastatinum: nIn systemic action it inhibits CYP3A4It slows the biotransformation increases the concentration in plasma and increases the risk of myopathy and rhabdomyolysis.

    Special instructions:

    Active monitoring of serum aminotransferases (before treatment and monthly during the first 3-4 months, with small deviations - the abolition of drugs), dermatological control.

    Avoid contact with mucous membranes of the eyes. When developing reactions of hypersensitivity or irritation, treatment with oxyconazole with nitrate should be stopped.

    In the treatment of fungal diseases of the external genital organs caused by drug-susceptible pathogens, simultaneous treatment of sexual partners is necessary.

    Impact on the ability to drive vehicles and manage mechanisms not found.

    Instructions
    Up